Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 324 clinical trials
None
HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART).

We at PGIMER have been practicing hypofractionated radiotherapy in breast cancer patients for the last 4 decades. Our standard doses have been 35Gy/15/3wks to the chest wall after mastectomy and 40Gy/16/3wks after breast conserving surgery (BCS).It is also a routine practice in the UK and in a few centers in …

mastectomy
invasive carcinoma
trastuzumab
hormone therapy
carcinoma
  • 0 views
  • 01 Jul, 2021
  • 1 location
None
PAlliative RAdioTherapy to Lung Cancer A Randomized Multicentre Phase III Study

The aim of this study is to examine if a shorter palliative radiotherapy fractionation scheme of 20 Gy / 4 F can reduce the early oesophageal toxicity compared to 30 Gy / 10 F in patients with lung cancer in performance status (PS) 0-2. Secondary aims are to examine the …

lung cancer
lung carcinoma
cancer
  • 2 views
  • 26 Jan, 2021
  • 1 location
None
EGFR-targeted Therapy for Gastric Cancer

Based on targeted NGS panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody (GC-1118) in combination with weekly paclitaxel as a second-line therapy.

  • 0 views
  • 24 May, 2021
  • 1 location
None
Matched Targeted Therapy For High-Risk Leukemias and MDS

specific cancer therapy or a clinical trial called matched targeted therapy (MTT). The results of the leukemia profiling and, if applicable, the MTT recommendation will be communicated to the

  • 0 views
  • 12 Jun, 2021
  • 15 locations
None
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab

A phase 2 open-label, randomized, multi-center trial to evaluate the efficacy and safety of neoadjuvant trastuzumab, pertuzumab and weekly paclitaxel (THP) as compared to neoadjuvant trastuzumab, pertuzumab, pembrolizumab and weekly paclitaxel (THP-K), or neoadjuvant trastuzumab, pembrolizumab and weekly paclitaxel (TH-K) in chemo naive patients with invasive human epidermal growth factor …

erbb2
primary tumor
her1
paclitaxel
epidermal growth factor receptor
  • 18 views
  • 08 Sep, 2021
  • 2 locations
None
Study of Targeted Therapy Using Transcription Activator-like Effector Nucleases in Cervical Precancerous Lesions

This is an open-label and triple cohort study of the safety and efficacy of T27 and T512 to possibly treat cervical intraepithelial neoplasia(CIN).

  • 1 views
  • 05 Feb, 2021
  • 1 location
None
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

patients undergoing endocrine-targeted therapy for newly diagnosed breast cancer or breast cancer that has come back or spread to other places in the body. Comparing results of diagnostic procedures done

  • 0 views
  • 10 Oct, 2021
  • 1 location
None
PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

Our goal is to investigate the use of 89Zr-trastuzumab as a HER2 imaging agent to determine which patients are likely to respond to targeted HER2 agents as single agent therapy. We are proposing to perform a pilot study with goals of demonstrating the feasibility of imaging breast cancer patients with …

HER2
erbb2
mammogram
trastuzumab
her2/neu-positive breast cancer
  • 38 views
  • 11 May, 2021
  • 1 location
None
A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

This research study is studying a type of radiation therapy called Stereotactic Body Radiation Therapy (SBRT) as a possible treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) or or displaced anaplastic lymphoma receptor tyrosine kinase (ALK) or ROS proto-oncogene 1 …

liver metastasis
tyrosine
anaplastic lymphoma
erlotinib
lymphoma
  • 0 views
  • 16 Feb, 2021
  • 1 location
None
177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.

The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin analogon, binding to cholecystokinin-2 receptors. This receptors show an overexpression on more than 90 % of medullary thyroid carcinomas. In the pilot …

ct scan
targeted therapy
cancer
gastrin
calcitonin
  • 11 views
  • 25 Jan, 2021
  • 1 location